Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.

Viale G, de Snoo FA, Slaets L, Bogaerts J, van 't Veer L, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Glas A, Russo L, Dell'Orto P, Tryfonidis K, Litière S, Cardoso F; MINDACT investigators.

Breast Cancer Res Treat. 2018 Jan;167(1):123-131. doi: 10.1007/s10549-017-4509-9. Epub 2017 Sep 19.

PMID:
28929359
2.

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.

Whitworth P, Beitsch P, Mislowsky A, Pellicane JV, Nash C, Murray M, Lee LA, Dul CL, Rotkis M, Baron P, Stork-Sloots L, de Snoo FA, Beatty J.

Ann Surg Oncol. 2017 Mar;24(3):669-675. doi: 10.1245/s10434-016-5600-x. Epub 2016 Oct 21.

3.

Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance.

Viale G, Slaets L, de Snoo FA, Bogaerts J, Russo L, van't Veer L, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Dell'Orto P, Glas AM, Cardoso F.

Breast Cancer Res Treat. 2016 Feb;155(3):463-9. doi: 10.1007/s10549-016-3690-6. Epub 2016 Jan 28.

4.

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy.

Baron P, Beitsch P, Boselli D, Symanowski J, Pellicane JV, Beatty J, Richards P, Mislowsky A, Nash C, Lee LA, Murray M, de Snoo FA, Stork-Sloots L, Gittleman M, Akbari S, Whitworth P.

Ann Surg Oncol. 2016 May;23(5):1522-9. doi: 10.1245/s10434-015-5030-1. Epub 2015 Dec 29.

5.

Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.

Drukker CA, Elias SG, Nijenhuis MV, Wesseling J, Bartelink H, Elkhuizen P, Fowble B, Whitworth PW, Patel RR, de Snoo FA, van 't Veer LJ, Beitsch PD, Rutgers EJ.

Breast Cancer Res Treat. 2014 Dec;148(3):599-613. doi: 10.1007/s10549-014-3188-z. Epub 2014 Nov 21. Erratum in: Breast Cancer Res Treat. 2015 Jan;149(2):567.

PMID:
25414025
6.

Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).

Whitworth P, Stork-Sloots L, de Snoo FA, Richards P, Rotkis M, Beatty J, Mislowsky A, Pellicane JV, Nguyen B, Lee L, Nash C, Gittleman M, Akbari S, Beitsch PD.

Ann Surg Oncol. 2014 Oct;21(10):3261-7. doi: 10.1245/s10434-014-3908-y. Epub 2014 Aug 7.

7.

High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.

Viale G, Slaets L, Bogaerts J, Rutgers E, van't Veer L, Piccart-Gebhart MJ, de Snoo FA, Stork-Sloots L, Russo L, Dell'Orto P, van den Akker J, Glas A, Cardoso F; TRANSBIG Consortium & the MINDACT Investigators.

Ann Oncol. 2014 Apr;25(4):816-23. doi: 10.1093/annonc/mdu026.

8.

MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue.

Sapino A, Roepman P, Linn SC, Snel MH, Delahaye LJ, van den Akker J, Glas AM, Simon IM, Barth N, de Snoo FA, van 't Veer LJ, Molinaro L, Berns EM, Wesseling J, Riley LB, Anderson D, Nguyen B, Cox CE.

J Mol Diagn. 2014 Mar;16(2):190-7. doi: 10.1016/j.jmoldx.2013.10.008. Epub 2013 Dec 28.

9.

Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation.

van der Rhee JI, Boonk SE, Putter H, Cannegieter SC, Flinterman LE, Hes FJ, de Snoo FA, Mooi WJ, Gruis NA, Vasen HF, Kukutsch NA, Bergman W.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1771-7. doi: 10.1158/1055-9965.EPI-13-0130. Epub 2013 Jul 29.

10.

Genome-wide analysis of gene and protein expression of dysplastic naevus cells.

Gao L, van Nieuwpoort FA, Out-Luiting JJ, Hensbergen PJ, de Snoo FA, Bergman W, van Doorn R, Gruis NA.

J Skin Cancer. 2012;2012:981308. doi: 10.1155/2012/981308. Epub 2012 Nov 28.

11.

Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients.

Nguyen B, Cusumano PG, Deck K, Kerlin D, Garcia AA, Barone JL, Rivera E, Yao K, de Snoo FA, van den Akker J, Stork-Sloots L, Generali D.

Ann Surg Oncol. 2012 Oct;19(10):3257-63. doi: 10.1245/s10434-012-2561-6. Epub 2012 Aug 15.

PMID:
22965266
12.

A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response.

Krijgsman O, Roepman P, Zwart W, Carroll JS, Tian S, de Snoo FA, Bender RA, Bernards R, Glas AM.

Breast Cancer Res Treat. 2012 May;133(1):37-47. doi: 10.1007/s10549-011-1683-z. Epub 2011 Aug 4.

PMID:
21814749
13.

Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A.

van der Rhee JI, Krijnen P, Gruis NA, de Snoo FA, Vasen HFA, Putter H, Kukutsch NA, Bergman W.

J Am Acad Dermatol. 2011 Aug;65(2):281-288. doi: 10.1016/j.jaad.2010.06.044. Epub 2011 May 12.

PMID:
21570156
14.

Effectiveness and causes for failure of surveillance of CDKN2A-mutated melanoma families.

van der Rhee JI, de Snoo FA, Vasen HFA, Mooi WJ, Putter H, Gruis NA, Kukutsch NA, Bergman W.

J Am Acad Dermatol. 2011 Aug;65(2):289-296. doi: 10.1016/j.jaad.2010.06.067. Epub 2011 May 12.

15.

Iatrogenic melanoma. Comment on: Melanoma epidemic: a midsummer night's dream?

van der Rhee JI, Mooi WJ, Kukutsch NA, de Snoo FA, Bergman W.

Br J Dermatol. 2010 Feb 1;162(2):457-8. doi: 10.1111/j.1365-2133.2009.09556.x. Epub 2009 Nov 16. No abstract available.

PMID:
19919631
16.

Selection criteria for genetic assessment of patients with familial melanoma.

Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarrà G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debniak T, Demierre MF, Elder D, Goldstein AM, Grant-Kels J, Halpern AC, Ingvar C, Kefford RF, Lang J, MacKie RM, Mann GJ, Mueller K, Newton-Bishop J, Olsson H, Petersen GM, Puig S, Rigel D, Swetter SM, Tucker MA, Yakobson E, Zitelli JA, Tsao H.

J Am Acad Dermatol. 2009 Oct;61(4):677.e1-14. doi: 10.1016/j.jaad.2009.03.016. Review.

17.

Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families.

de Snoo FA, Bishop DT, Bergman W, van Leeuwen I, van der Drift C, van Nieuwpoort FA, Out-Luiting CJ, Vasen HF, ter Huurne JA, Frants RR, Willemze R, Breuning MH, Gruis NA.

Clin Cancer Res. 2008 Nov 1;14(21):7151-7. doi: 10.1158/1078-0432.CCR-08-0403.

18.

Genetic testing in familial melanoma: uptake and implications.

de Snoo FA, Riedijk SR, van Mil AM, Bergman W, ter Huurne JA, Timman R, Bertina W, Gruis NA, Vasen HF, van Haeringen A, Breuning MH, Tibben A.

Psychooncology. 2008 Aug;17(8):790-6. doi: 10.1002/pon.1377.

PMID:
18613292
19.

Genome-wide linkage scan for atypical nevi in p16-Leiden melanoma families.

de Snoo FA, Hottenga JJ, Gillanders EM, Sandkuijl LA, Jones MP, Bergman W, van der Drift C, van Leeuwen I, van Mourik L, Huurne JA, Frants RR, Willemze R, Breuning MH, Trent JM, Gruis NA.

Eur J Hum Genet. 2008 Sep;16(9):1135-41. doi: 10.1038/ejhg.2008.72. Epub 2008 Apr 9.

20.

From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in sporadic atypical nevus patients.

de Snoo FA, Kroon MW, Bergman W, ter Huurne JA, Houwing-Duistermaat JJ, van Mourik L, Snels DG, Breuning MH, Willemze R, Frants RR, Gruis NA.

J Am Acad Dermatol. 2007 May;56(5):748-52. Epub 2007 Feb 5.

PMID:
17276542
21.

High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.

Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E; Melanoma Genetics Consortium (GenoMEL).

Cancer Res. 2006 Oct 15;66(20):9818-28.

22.

Cutaneous melanoma susceptibility and progression genes.

de Snoo FA, Hayward NK.

Cancer Lett. 2005 Dec 18;230(2):153-86. Review.

PMID:
16297704
23.

A mutation hotspot at the p14ARF splice site.

Harland M, Taylor CF, Chambers PA, Kukalizch K, Randerson-Moor JA, Gruis NA, de Snoo FA, ter Huurne JA, Goldstein AM, Tucker MA, Bishop DT, Bishop JA.

Oncogene. 2005 Jun 30;24(28):4604-8.

PMID:
15856016
24.

Hereditary melanoma and predictive genetic testing: why not?

Riedijk SR, de Snoo FA, van Dijk S, Bergman W, van Haeringen A, Silberg S, van Elderen TM, Tibben A.

Psychooncology. 2005 Sep;14(9):738-45.

PMID:
15744786
25.

Familial melanoma: a complex disorder leading to controversy on DNA testing.

de Snoo FA, Bergman W, Gruis NA.

Fam Cancer. 2003;2(2):109-16. Review.

PMID:
14574160
26.

Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).

de vos tot Nederveen Cappel WH, Offerhaus GJ, van Puijenbroek M, Caspers E, Gruis NA, De Snoo FA, Lamers CB, Griffioen G, Bergman W, Vasen HF, Morreau H.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3598-605.

Supplemental Content

Loading ...
Support Center